Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) trades at $7.60 with AI Score 40/100 (Grade C). Shanghai Pharmaceuticals Holding Co. , Ltd. Market cap: $5.64B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SHPMY: SHPMY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHPMY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHPMY: 1/1 perspectives are bearish.
How is this calculated? →Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Healthcare & Pipeline Overview
Shanghai Pharmaceuticals Holding Co., Ltd., a major player in the Chinese pharmaceutical sector, focuses on the entire value chain from R&D and manufacturing to distribution and retail. With a diverse product portfolio and a wide network of retail pharmacies, it addresses key therapeutic areas while navigating the evolving healthcare landscape in China.
What Is the Investment Thesis for SHPMY?
Shanghai Pharmaceuticals Holding Co., Ltd. presents a compelling investment case based on its integrated business model and strong market position in China. The company's diverse product portfolio and extensive distribution network provide a stable revenue base. With a P/E ratio of 10.2 and a dividend yield of 2.37%, the stock offers potential value and income. Growth catalysts include expanding its retail pharmacy network and increasing its focus on innovative drugs. However, investors may want to evaluate the regulatory risks and competitive pressures in the Chinese pharmaceutical market, as well as the impact of currency fluctuations on its ADR.
Based on FMP financials and quantitative analysis
SHPMY Key Highlights
- Market capitalization of $5.64B, reflecting its significant presence in the Chinese pharmaceutical market.
- P/E ratio of 10.2, suggesting a potentially undervalued stock compared to its earnings.
- Profit margin of 2.0%, indicating room for improvement in operational efficiency.
- Gross margin of 10.6%, highlighting the need to optimize production and distribution costs.
- Dividend yield of 2.37%, providing a steady income stream for investors.
Who Are SHPMY's Competitors?
SHPMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVVF ConvaTec Group Plc | $2.73 | +0.00% | $5.32B | 49 |
| CNVVY ConvaTec Group Plc | $11.74 | +0.41% | $5.74B | 43 |
| DSRLF DiaSorin S.p.A. | $84.10 | +13.27% | $4.16B | 52 |
| GNGBY Getinge AB (publ) | $21.24 | +0.80% | $5.78B | 47 |
| GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.20B | 43 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHPMY's Key Strengths?
- Integrated business model covering R&D, manufacturing, distribution, and retail.
- Extensive distribution network across China.
- Diverse product portfolio catering to various therapeutic areas.
- Established brand reputation in the Chinese pharmaceutical market.
What Are SHPMY's Weaknesses?
- Relatively low profit margin compared to global peers.
- Dependence on the Chinese market.
- Exposure to regulatory changes and pricing pressures.
- Limited international presence.
What Could Drive SHPMY Stock Higher?
- Potential regulatory approvals for new drugs in the pipeline.
- Expansion of the retail pharmacy network across China.
- Increasing demand for pharmaceutical products due to an aging population.
- Growth in the online drug business and e-commerce trends.
What Are the Key Risks for SHPMY?
- Regulatory changes and pricing pressures in the Chinese pharmaceutical market.
- Currency fluctuations impacting ADR value.
- Increasing competition from domestic and international players.
- Supply chain disruptions affecting manufacturing and distribution.
- Dependence on the Chinese market.
What Are the Growth Opportunities for SHPMY?
- Expansion of Retail Pharmacy Network: Shanghai Pharmaceuticals can grow by expanding its network of retail pharmacies across China. With approximately 2,000 retail chain pharmacies currently, there is potential to increase market share by penetrating underserved regions and offering value-added services like telemedicine and chronic disease management. The Chinese retail pharmacy market is projected to reach $300 billion by 2028, presenting a significant opportunity for growth.
- Development of Innovative Drugs: Investing in research and development to create innovative drugs can drive long-term growth. Focusing on high-demand therapeutic areas like oncology and CNS disorders can lead to higher-margin products and increased market share. The global market for innovative drugs is expected to reach $1.2 trillion by 2030, offering substantial revenue potential.
- Strengthening Distribution Network: Optimizing and expanding its pharmaceutical distribution network can improve efficiency and reach. Investing in advanced logistics and supply chain technologies can reduce costs and enhance service quality. The Chinese pharmaceutical distribution market is expected to grow at a CAGR of 8% over the next five years, driven by increasing demand for pharmaceuticals.
- Online Drug Business Expansion: Growing its online drug business can tap into the increasing trend of online healthcare and e-commerce. Offering a wider range of products and services online, along with convenient delivery options, can attract new customers and increase sales. The online pharmacy market in China is projected to reach $100 billion by 2027, presenting a significant growth opportunity.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies and acquiring smaller players can expand its product portfolio and market reach. Collaborating with international companies can also provide access to new technologies and markets. The pharmaceutical industry is witnessing increasing consolidation, and strategic alliances can enhance competitiveness.
What Opportunities Does SHPMY Have?
- Expanding retail pharmacy network in underserved regions.
- Investing in research and development of innovative drugs.
- Growing online drug business to tap into e-commerce trends.
- Forming strategic partnerships and acquisitions to expand market reach.
What Threats Does SHPMY Face?
- Increasing competition from domestic and international players.
- Regulatory changes and pricing pressures affecting profitability.
- Currency fluctuations impacting ADR value.
- Potential supply chain disruptions.
What Are SHPMY's Competitive Advantages?
- Extensive Distribution Network: Its widespread distribution network provides a significant competitive advantage in reaching customers across China.
- Diverse Product Portfolio: A broad range of pharmaceutical products reduces reliance on any single product and caters to various therapeutic areas.
- Established Brand Reputation: A long history and established brand name in the Chinese pharmaceutical market provide trust and recognition.
- Integrated Business Model: Its integrated model, covering R&D, manufacturing, distribution, and retail, provides greater control and efficiency.
What Does SHPMY Do?
Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it operates across four segments: Production, Distribution, Retail, and Others. The Production segment focuses on manufacturing a diverse range of pharmaceutical products, including chemicals, biochemicals, Chinese medicines, healthcare products, and medical devices. These products target therapeutic areas such as oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. The Distribution segment provides pharmaceutical distribution, warehousing, and logistics services to manufacturers, hospitals, distributors, and retail pharmacies. The Retail segment operates a network of approximately 2,000 retail chain pharmacies across 24 provinces, along with an online drug business. The company also offers consulting services, asset management, clinical trials, medical aid, physician education, e-prescription management, and remote hospital services. Shanghai Pharmaceuticals Holding Co., Ltd. plays a critical role in the Chinese healthcare ecosystem, providing a comprehensive suite of products and services.
What Products and Services Does SHPMY Offer?
- Researches and develops pharmaceutical products.
- Manufactures a wide range of drugs and healthcare products.
- Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
- Operates a network of approximately 2,000 retail chain pharmacies.
- Provides pharmaceutical supply chain solutions and related services.
- Engages in online drug business.
- Offers consulting services and asset management operations.
- Conducts clinical trials and provides medical aid.
How Does SHPMY Make Money?
- Generates revenue from the sale of manufactured pharmaceutical products.
- Earns fees from providing pharmaceutical distribution and logistics services.
- Derives income from retail sales through its pharmacy network.
- Receives revenue from online drug sales.
- Provides consulting and asset management services for additional income.
What Industry Does SHPMY Operate In?
Shanghai Pharmaceuticals Holding Co., Ltd. operates in the rapidly growing Chinese pharmaceutical market. The industry is driven by increasing healthcare spending, an aging population, and rising chronic disease prevalence. The company competes with other major pharmaceutical distributors and manufacturers, including CNVVF (China National Medicines Corporation Ltd), CNVVY (Sinopharm Group Co Ltd), DSRLF (D S Healthcare Holdings Ltd), GNGBY (Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd), and GZPHF (Guangzhou Pharmaceutical Co Ltd). Regulatory changes and pricing pressures pose ongoing challenges, but also create opportunities for companies with strong distribution networks and innovative product pipelines.
Who Are SHPMY's Key Customers?
- Hospitals and healthcare institutions.
- Pharmaceutical distributors and wholesalers.
- Retail pharmacies.
- Individual consumers through retail pharmacies and online channels.
- Pharmaceutical manufacturers.
FY2026 estForward Outlook
Wall Street analysts project Shanghai Pharmaceuticals Holding Co., Ltd revenue of about $298.01B for fiscal 2026, with EPS near $0.00. The estimate reflects 9 contributing analysts.
SHPMY Valuation & Market Position
With a $5.64B market cap, Shanghai Pharmaceuticals Holding Co., Ltd sits in the mid-cap segment of the market. Relative to its peer group, SHPMY's quantitative score of 40/100 is roughly in line with the peer average of 47/100.
ROE 8%Key Financial Metrics
Return on equity for Shanghai Pharmaceuticals Holding Co., Ltd stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. SHPMY trades at a trailing price-to-earnings ratio of 10.16, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Shanghai Pharmaceuticals Holding Co., Ltd's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.98 places it in the grey zone, a middle ground that warrants monitoring.
Company Profile
Shanghai Pharmaceuticals Holding Co., Ltd operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Qiuhua Yang. SHPMY has traded publicly since 2014.
SHPMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a positive outlook from leadership.
- Community sentiment has shifted positively as discussions about Shanghai Pharmaceuticals' expanding market presence have gained traction.
- The company's strategic partnerships in the healthcare sector are being recognized, enhancing its reputation and potential for growth.
- Recent product launches have been well-received, leading to increased optimism among investors and analysts alike.
Bear Case
- Concerns about regulatory challenges in the pharmaceutical industry have surfaced, leading to skepticism among some investors.
- Recent market developments have highlighted increased competition, which may impact Shanghai Pharmaceuticals' market share.
- Bearish sentiment has arisen due to uncertainties surrounding global supply chain disruptions affecting pharmaceutical manufacturing.
- Analysts are cautious about the sustainability of recent growth, questioning whether it can be maintained in the face of economic headwinds.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SHPMY Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
SHPMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHPMY.
Price Targets
Wall Street price target analysis for SHPMY.
SHPMY MoonshotScore
What does this score mean?
The MoonshotScore rates SHPMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Qiuhua Yang
Unknown
Information on Qiuhua Yang's background is not available in the provided context. Details regarding their education, previous roles, and career history are unknown. Further research would be needed to provide a comprehensive profile.
Track Record: Information on Qiuhua Yang's track record is not available in the provided context. Specific achievements, strategic decisions, and company milestones under their leadership are unknown. Further research would be needed to assess their performance.
Shanghai Pharmaceuticals Holding Co., Ltd ADR Information Unsponsored
An American Depositary Receipt (ADR) like SHPMY represents shares of a foreign company (Shanghai Pharmaceuticals) held by a U.S. depositary bank. SHPMY allows U.S. investors to trade shares of Shanghai Pharmaceuticals on the OTC market in U.S. dollars, simplifying investment in the Chinese market.
- Home Market Ticker: Shanghai Stock Exchange, China
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SHPM
SHPMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies on this tier often have limited financial disclosure, may not meet minimum listing standards, and carry higher risks compared to companies listed on exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires extra due diligence due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consider seeking professional financial advice.
- Monitor trading volume and price movements.
- Subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
- Operations in the highly regulated pharmaceutical industry.
- Presence in the Chinese market since 1994.
- Extensive distribution network and retail pharmacy operations.
Shanghai Pharmaceuticals Holding Co., Ltd Healthcare Stock: Key Questions Answered
What does Shanghai Pharmaceuticals Holding Co., Ltd do?
Shanghai Pharmaceuticals Holding Co., Ltd. is a comprehensive pharmaceutical company that operates across the entire value chain, from research and development to manufacturing, distribution, and retail. It produces and distributes a wide range of pharmaceutical products, including chemicals, biochemicals, Chinese medicines, healthcare products, and medical devices. The company also operates a large network of retail pharmacies and provides pharmaceutical supply chain solutions. This integrated model allows it to capture value at multiple stages and maintain a strong presence in the Chinese healthcare market.
What do analysts say about SHPMY stock?
Analyst coverage of SHPMY is limited due to its OTC listing and ADR status. However, the company's financial performance and strategic initiatives are closely monitored. Key valuation metrics include its P/E ratio of 10.2 and dividend yield of 2.37%. Growth considerations include its expansion plans, R&D pipeline, and exposure to the Chinese pharmaceutical market. Investors should conduct their own research and consider their risk tolerance before investing.
What are the main risks for SHPMY?
The main risks for Shanghai Pharmaceuticals Holding Co., Ltd. include regulatory changes and pricing pressures in the Chinese pharmaceutical market, which can impact profitability. Currency fluctuations can also affect the value of its ADR for U.S. investors. Increasing competition from both domestic and international players poses a threat to its market share. Additionally, potential supply chain disruptions and its dependence on the Chinese market are ongoing concerns.
What are the key factors to evaluate for SHPMY?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) holds an AI score of 40/100 (low). P/E: 10.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SHPMY data refresh on this page?
SHPMY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHPMY's recent stock price performance?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated business model covering R&D, manufacturing, distribution, and retail. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHPMY overvalued or undervalued right now?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) trades at 10.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SHPMY?
Before investing in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market investments carry higher risks than exchange-listed stocks.
- AI analysis is pending and may provide further insights.